Skip to search formSkip to main contentSkip to account menu

Glucantime

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Meglumine antimonate is the active of Glucantime® used for the treatment of leishmaniasis, a tropical disease caused by parasitic… 
2009
2009
Background: The aromatic herb Chenopodium ambrosioides is widely known for its antiparasitic activity. The aim of this study was… 
2007
2007
Introduction: Cutaneous leishmaniasis is endemic in Iran. Fasa region (Southern west of Iran) is one of the hot spots. The most… 
2006
2006
OBJECTIVE The treatment of cutaneous leishmaniasis used in Tunisia is Glucantime. The aim of this retrospective study was to… 
2005
2005
PURPOSE The labeling of red blood cells (C) with 99mTc is employed in clinical nuclear medicine for a variety of diagnostic… 
2004
2004
Growth inhibition ofLeishmania promastigotes by glucantime was compared in three different media. Glucantime inhibited the growth… 
2002
2002
There are evidences that some drugs used for the human diseases can modify the biodistribution of radiopharmaceuticals. The N… 
2002
2002
A 70‐year‐old white Brazilian woman from a rural area had a 2‐year history of a painful lesion on her left toe. The lesion… 
1997
1997
We treated six patients with mucosal leishmaniasis who failed to respond to glucantime (20 mg/kg/day) with ambisome (2-5 grams… 
1985
1985
The therapeutic efficacy of CP-46,665-1, a synthetic lipoidal amine with proven immunomodulatory and anti-tumor properties, in…